

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6606)**

**APPOINTMENT OF AUDITOR  
AND  
CONTINUED SUSPENSION OF TRADING**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2)(a) and Rule 13.51(4) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated March 28, 2024 in relation to the suspension of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on March 28, 2024; (ii) the announcement of the Company dated March 28, 2024 in relation to, among others, the delay in publication of the 2023 Annual Results; (iii) the announcement of the Company dated April 8, 2024 in relation to, among others, the establishment of the Independent Special Committee; (iv) the announcement of the Company dated May 28, 2024 on the Resumption Guidance from the Stock Exchange; (v) the announcement of the Company dated June 28, 2024 in relation to the first quarterly update on resumption progress; and (vi) the announcement of the Company dated September 9, 2024 in relation to the resignation of auditor (collectively, the “**Announcements**”).

Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the Announcements.

**APPOINTMENT OF AUDITOR**

In view of the vacancy in the office of auditor of the Company following the resignation of Deloitte Touche Tohmatsu, the Board has resolved, with the recommendation of the Audit Committee, to appoint ZHONGHUI ANDA CPA Limited (中匯安達會計師事務所有限公司) (“**Zhonghui Anda**”) as the new auditor of the Company with effect from September 27, 2024, and to hold office until the conclusion of the next annual general meeting of the Company (the “**Appointment**”).

In assessing the appointment of Zhonghui Anda as the auditor of the Company, the Audit Committee has considered a number of factors, including but not limited to (i) its experience, resources, capabilities and manpower; (ii) its understanding of the Company's current situation and its willingness to invest sufficient resources to effectively and fully implement the audit procedures; (iii) the audit fee proposed by Zhonghui Anda; and (iv) the guidelines issued by the Accounting and Financial Reporting Council.

Based on the above, the Audit Committee has assessed and considered Zhonghui Anda independent, competent and capable to act as the new auditor of the Company. The Board and the Audit Committee are of the view that the Appointment is in the interest of the Company and the Shareholders as a whole.

The Board would like to take this opportunity to express its welcome to Zhonghui Anda on its appointment as the new auditor of the Company.

### **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended pending fulfilment of the Resumption Guidance.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**New Horizon Health Limited**  
**Mr. YeQing ZHU**  
*Chairman*

Hong Kong, September 27, 2024

*As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU, Dr. Donald Kwok Tung LI, Mr. LAU Ngai Kee Ricky and Ms. NG Weng Sin as independent non-executive Directors.*